Literature DB >> 23249231

Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence.

Brian M Olson1, Douglas G McNeel.   

Abstract

EVALUATION OF: Jensen SM, Twitty CG, Maston LD et al. Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence. J. Immunol. 189(2), 767-776 (2012). While tumor immunotherapy has seen notable success in recent years, mechanisms that tumors utilize to escape immune responses have provided significant hurdles to maximal clinical benefit. Escape mechanisms such as antigen loss, decreased MHC expression, as well as tumor-mediated suppressive effects on antitumor immune responses, can cause the most potent antitumor immune response to be rendered powerless at the tumor site. In this study, the authors show that the adoptive transfer of tumor antigen-specific CD4(+) and CD8(+) T cells combined with tumor cell immunization can elicit regression of established subcutaneous tumors in lymphopenic, but not lymphoreplete, animals. However, using a suboptimal dose of transferred cells followed by vaccination, the authors identify the development of recurrent tumors with reduced antigen expression. These tumors could still be eradicated in similarly treated animals; however, they found that transferred CD4(+) T cells from animals with recurrent tumors acquired a suppressive phenotype. This work highlights the importance of understanding mechanisms of tumor escape, particularly underscoring the role of the tumor in modulating antigen-specific immune responses, and the critical importance of finding mechanisms to avoid the development of viable escape variants.

Entities:  

Year:  2012        PMID: 23249231      PMCID: PMC3557828          DOI: 10.1586/erv.12.107

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  8 in total

1.  Development of antitumor immune responses in reconstituted lymphopenic hosts.

Authors:  Hong-Ming Hu; Christian H Poehlein; Walter J Urba; Bernard A Fox
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

2.  Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence.

Authors:  Shawn M Jensen; Christopher G Twitty; Levi D Maston; Paul A Antony; May Lim; Hong-Ming Hu; Ulf Petrausch; Nicholas P Restifo; Bernard A Fox
Journal:  J Immunol       Date:  2012-06-20       Impact factor: 5.422

3.  IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

Authors:  V Shankaran; H Ikeda; A T Bruce; J M White; P E Swanson; L J Old; R D Schreiber
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

Review 4.  Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Authors:  Hung T Khong; Nicholas P Restifo
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

5.  Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors:  Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  Science       Date:  2002-09-19       Impact factor: 47.728

Review 6.  Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.

Authors:  Murrium Ahmad; Robert C Rees; Selman A Ali
Journal:  Cancer Immunol Immunother       Date:  2004-06-10       Impact factor: 6.968

7.  Expression of tumour-specific antigens underlies cancer immunoediting.

Authors:  Michel DuPage; Claire Mazumdar; Leah M Schmidt; Ann F Cheung; Tyler Jacks
Journal:  Nature       Date:  2012-02-08       Impact factor: 49.962

8.  Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression.

Authors:  Gang Zhou; Zhengbin Lu; John D McCadden; Hyam I Levitsky; Aimee L Marson
Journal:  J Exp Med       Date:  2004-12-13       Impact factor: 14.307

  8 in total
  13 in total

1.  Inhibition of tumor growth and metastasis by EMMPRIN multiple antigenic peptide (MAP) vaccination is mediated by immune modulation.

Authors:  Elina Simanovich; Vera Brod; Maya M Rahat; Ella Drazdov; Miriam Walter; Jivan Shakya; Michal A Rahat
Journal:  Oncoimmunology       Date:  2016-11-29       Impact factor: 8.110

2.  Trial watch: Naked and vectored DNA-based anticancer vaccines.

Authors:  Norma Bloy; Aitziber Buqué; Fernando Aranda; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Catherine Sautès-Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

3.  Co-delivery of human cancer-testis antigens with adjuvant in protein nanoparticles induces higher cell-mediated immune responses.

Authors:  Medea Neek; Jo Anne Tucker; Tae Il Kim; Nicholas M Molino; Edward L Nelson; Szu-Wen Wang
Journal:  Biomaterials       Date:  2017-11-20       Impact factor: 12.479

4.  Surface engineering tumor cells with adjuvant-loaded particles for use as cancer vaccines.

Authors:  Kawther K Ahmed; Sean M Geary; Aliasger K Salem
Journal:  J Control Release       Date:  2017-01-03       Impact factor: 9.776

Review 5.  Trial Watch: Peptide-based anticancer vaccines.

Authors:  Jonathan Pol; Norma Bloy; Aitziber Buqué; Alexander Eggermont; Isabelle Cremer; Catherine Sautès-Fridman; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-01-09       Impact factor: 8.110

Review 6.  Classification of current anticancer immunotherapies.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; José-Manuel Bravo-San Pedro; Aitziber Buqué; Laura Senovilla; Elisa Elena Baracco; Norma Bloy; Francesca Castoldi; Jean-Pierre Abastado; Patrizia Agostinis; Ron N Apte; Fernando Aranda; Maha Ayyoub; Philipp Beckhove; Jean-Yves Blay; Laura Bracci; Anne Caignard; Chiara Castelli; Federica Cavallo; Estaban Celis; Vincenzo Cerundolo; Aled Clayton; Mario P Colombo; Lisa Coussens; Madhav V Dhodapkar; Alexander M Eggermont; Douglas T Fearon; Wolf H Fridman; Jitka Fučíková; Dmitry I Gabrilovich; Jérôme Galon; Abhishek Garg; François Ghiringhelli; Giuseppe Giaccone; Eli Gilboa; Sacha Gnjatic; Axel Hoos; Anne Hosmalin; Dirk Jäger; Pawel Kalinski; Klas Kärre; Oliver Kepp; Rolf Kiessling; John M Kirkwood; Eva Klein; Alexander Knuth; Claire E Lewis; Roland Liblau; Michael T Lotze; Enrico Lugli; Jean-Pierre Mach; Fabrizio Mattei; Domenico Mavilio; Ignacio Melero; Cornelis J Melief; Elizabeth A Mittendorf; Lorenzo Moretta; Adekunke Odunsi; Hideho Okada; Anna Karolina Palucka; Marcus E Peter; Kenneth J Pienta; Angel Porgador; George C Prendergast; Gabriel A Rabinovich; Nicholas P Restifo; Naiyer Rizvi; Catherine Sautès-Fridman; Hans Schreiber; Barbara Seliger; Hiroshi Shiku; Bruno Silva-Santos; Mark J Smyth; Daniel E Speiser; Radek Spisek; Pramod K Srivastava; James E Talmadge; Eric Tartour; Sjoerd H Van Der Burg; Benoît J Van Den Eynde; Richard Vile; Hermann Wagner; Jeffrey S Weber; Theresa L Whiteside; Jedd D Wolchok; Laurence Zitvogel; Weiping Zou; Guido Kroemer
Journal:  Oncotarget       Date:  2014-12-30

7.  Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo.

Authors:  A Sergeeva; H He; K Ruisaard; L St John; G Alatrash; K Clise-Dwyer; D Li; R Patenia; R Hong; P Sukhumalchandra; M J You; M Gagea; Q Ma; J J Molldrem
Journal:  Leukemia       Date:  2016-03-08       Impact factor: 11.528

8.  RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.

Authors:  Dennis C Harrer; Bianca Simon; Shin-Ichiro Fujii; Kanako Shimizu; Ugur Uslu; Gerold Schuler; Kerstin F Gerer; Stefanie Hoyer; Jan Dörrie; Niels Schaft
Journal:  BMC Cancer       Date:  2017-08-17       Impact factor: 4.430

Review 9.  Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?

Authors:  Thomas C Wirth; Florian Kühnel
Journal:  Front Immunol       Date:  2017-12-19       Impact factor: 7.561

10.  The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma.

Authors:  Bianca Simon; Manuel Wiesinger; Johannes März; Kilian Wistuba-Hamprecht; Benjamin Weide; Beatrice Schuler-Thurner; Gerold Schuler; Jan Dörrie; Ugur Uslu
Journal:  Int J Mol Sci       Date:  2018-08-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.